Javascript must be enabled to continue!
Efficacy and safety of coenzyme Q10 supplement on simvastatin induced myalgia and transaminase increment
View through CrossRef
Objective
To investigate whether Coenzyme Q10 (CoQ10) supplement can help ease or eliminate some of the side effects that result from taking simvastatin medication in coronary artery disease (CAD) patients with hypercholesterolemia. These side effects include myalgia, fatigue and Transaminase Increment.
Methods
198 CAD patients with hypercholesterolemia were randomised to CoQ10 (30 mg/day) plus simvastatin (40 mg/day) as therapy group (n=99) or placebo plus simvastatin (40 mg/day) as control group (n=99). The incidence of myalgia and fatigue in the two groups were compared in 3 months after treatment. Plasma CoQ10 level, creatine kinase (CK), transaminase (ALT, AST) and blood lipids (TC, TG, LDL-C, HDL-C) were measured at baseline, 1 month and 3 months after treatment.
Results
The incidence of myalgia and fatigue demonstrated a decrease in therapy group compared with control group (3% vs 12%, p<0.01). Plasma CoQ10 level was no significant difference in therapy group in 1 month and 3 months after treatment, but in the control group, there was obviously decreased in both 1 month and 3 months after treatment compared with baseline (0.43±0.16 vs 0.51±0.13, 0.39±0.14 vs 0.51±0.13, p<0.05). CK, ALT and AST of pre and post therapy had no significant difference in therapy group (p>0.05), but in control group CK, ALT and AST were all increased significantly in 3 months compared with baseline. TC, TG and LDL-C were decreased significantly (p<0.01) both in therapy and control group post-therapy.
Conclusion
Simvastatin causes a marked decrease in plasma CoQ10 level in CAD patients. CoQ10 supplement can reduce myalgia and fatigue occurrence, decrease transaminase and creatine kinase increase caused by simvastatin. These data suggest that simvastatin related myopathy is associated with decrease in blood CoQ10 level. Widespread inhibition of CoQ10 synthesis could explain the most commonly reported adverse effects of simvastatins, especially myalgia, fatigue and rhabdomyolysis. So the combination of CoQ10 and simvastatins is safe and effective in CAD patients complicated by hypercholesterolemia.
Title: Efficacy and safety of coenzyme Q10 supplement on simvastatin induced myalgia and transaminase increment
Description:
Objective
To investigate whether Coenzyme Q10 (CoQ10) supplement can help ease or eliminate some of the side effects that result from taking simvastatin medication in coronary artery disease (CAD) patients with hypercholesterolemia.
These side effects include myalgia, fatigue and Transaminase Increment.
Methods
198 CAD patients with hypercholesterolemia were randomised to CoQ10 (30 mg/day) plus simvastatin (40 mg/day) as therapy group (n=99) or placebo plus simvastatin (40 mg/day) as control group (n=99).
The incidence of myalgia and fatigue in the two groups were compared in 3 months after treatment.
Plasma CoQ10 level, creatine kinase (CK), transaminase (ALT, AST) and blood lipids (TC, TG, LDL-C, HDL-C) were measured at baseline, 1 month and 3 months after treatment.
Results
The incidence of myalgia and fatigue demonstrated a decrease in therapy group compared with control group (3% vs 12%, p<0.
01).
Plasma CoQ10 level was no significant difference in therapy group in 1 month and 3 months after treatment, but in the control group, there was obviously decreased in both 1 month and 3 months after treatment compared with baseline (0.
43±0.
16 vs 0.
51±0.
13, 0.
39±0.
14 vs 0.
51±0.
13, p<0.
05).
CK, ALT and AST of pre and post therapy had no significant difference in therapy group (p>0.
05), but in control group CK, ALT and AST were all increased significantly in 3 months compared with baseline.
TC, TG and LDL-C were decreased significantly (p<0.
01) both in therapy and control group post-therapy.
Conclusion
Simvastatin causes a marked decrease in plasma CoQ10 level in CAD patients.
CoQ10 supplement can reduce myalgia and fatigue occurrence, decrease transaminase and creatine kinase increase caused by simvastatin.
These data suggest that simvastatin related myopathy is associated with decrease in blood CoQ10 level.
Widespread inhibition of CoQ10 synthesis could explain the most commonly reported adverse effects of simvastatins, especially myalgia, fatigue and rhabdomyolysis.
So the combination of CoQ10 and simvastatins is safe and effective in CAD patients complicated by hypercholesterolemia.
Related Results
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Background:
Cisplatin is an anticancer drug used in the management of solid tumors,
however, dose-related nephrotoxicity is one of its major problems. Agents having antioxidants, a...
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
Objective
To investigate the effects of simvastatin on myocardial angiogenesis and the expression of angiopoietin-1 after experimental myocardial infarction (MI) ...
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
Objective
To investigate the roles of angiopoietin-1 (Ang-1) and endothelial nitric oxide synthase (eNOS) in pro-angiogenic effect of simvastatin after experiment...
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
Objectives
To investigate the effects of simvastatin therapy on vascular endothelial function in patients with coronary heart diseases (CAD).
...
Simvastatin dengan Senyawa Turunan Β-Siklodextrin
Simvastatin dengan Senyawa Turunan Β-Siklodextrin
This study aims to determine the profile of the inclusion complex formed between simvastatin and β-cyclodextrin and its derivatives. To determine the level of stability and determi...
Effect of coenzyme Q10 concentration on post-freezing ovine semen
Effect of coenzyme Q10 concentration on post-freezing ovine semen
Reproductive biotechnologies have become a fundamental component for increasing productive efficiency. These tools address issues related to infertility and productivity i...
Simvastatin suppressed HMGB1-RAGE axis and atherosclerosis via mevalonate pathway
Simvastatin suppressed HMGB1-RAGE axis and atherosclerosis via mevalonate pathway
Objective
Recent studies suggested that high mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) contribute to atherosclerosis, a...
SIMVASTATIN ATTENUATES RENAL FAILURE IN MICE WITH A 5/6 SUBTOTAL NEPHRECTOMY
SIMVASTATIN ATTENUATES RENAL FAILURE IN MICE WITH A 5/6 SUBTOTAL NEPHRECTOMY
Objective: The objective of this study to investigate the effect of simvastatin on kidney fibrosis in mice with a 5/6 subtotal nephrectomy.Methods: Thirty adults (3 mo old) male Sw...

